The company will provide its lead cell permeable peptide targeting inflammatory diseases to Dr. Robert Nussenblatt to investigate its efficacy in animal models of uveitis.
Portage will also be responsible for providing financial support for these studies.
Portage Pharmaceuticals CEO Bruce Littman said, "This agreement will enable Portage to benefit from Dr. Nussenblatt’s great depth of knowledge and experience in the area of inflammatory eye diseases while providing tools to further the understanding of the pathogenesis of these diseases and possibly a new therapeutic approach that could be a great benefit to patients."
Portage is focused in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs.
After proof of concept, the company will look to sell or license the products to large pharmaceutical companies for further development and commercialization.